NOVARTIS

Kura Oncology secures $330 million from Kyowa Kirin for ziftomenib, a menin inhibitor targeting KMT2A-mutated leukemia, with plans for FDA submission in 2025. The collaboration aims to develop ziftomenib across leukemias and solid tumors, with potential milestone payments up to $1.2 billion.

Radiopharmaceuticals, combining radioactive isotopes with targeted molecules, revolutionize cancer detection and treatment, offering precise therapies with minimal damage to healthy tissues. The market is rapidly growing, driven by advancements in radioisotope-based therapies and increasing cancer incidence. Key players like Radiopharm Theranostics and partnerships with institutions like MD Anderson Cancer Center highlight innovation and investment potential in this field.

Novartis acquires Kate Therapeutics for up to $1.1 billion, expanding its neuroscience and gene therapy portfolio. KateTx focuses on AAV-based gene therapies for neuromuscular diseases, aiming to improve efficacy and safety by avoiding off-target tissues like the liver. Key programs include treatments for XLMTM, DMD, FSHD, and DM1. The acquisition is expected to enhance Novartis' ability to develop new therapies for neuromuscular diseases.

Huntington's disease treatments face challenges due to rarity and trial failures, but recent milestones like Wave's WVE-003, Roche-Ionis' tominersen, uniQure's AMT-130, and PTC Therapeutics' PTC518 offer hope. Prilenia's pridopidine is under EMA review, while Annexon's ANX005 and Sage's dalzanemdor faced setbacks. Despite these, cautious optimism remains for effective treatments.

The non-small cell lung cancer market is driven by increasing NSCLC cases, uptake of immune checkpoint inhibitors, emerging premium therapies, and awareness of mutations. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size from 2019 to 2032 in 7MM. Key companies and therapies include EMD Serono, Merck, AstraZeneca, Bristol-Myers Squibb, and therapies like M1774, C-TIL051, and Osimertinib. FDA approvals for Opdivo and Tagrisso in 2024 highlight advancements in treatment.

DelveInsight's report on Thrombocytopenia Market (2034) covers epidemiology, market trends in the US, EU4, UK, and Japan, highlighting the US as the largest market. Key companies include Sanofi, Principia Biopharma, Baxalta, Takeda, and others. Promising therapies such as VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, and Nipocalimab are noted. Clinical trials by Qidong Gaitianli Medicines, Karyopharm Therapeutics, Janssen Research & Development, and Amgen are scheduled for June 2024. Marketed drugs like ADZYNMA (Takeda) and TAVALISSE (Rigel Pharmaceuticals/Kissei Pharmaceutical) are discussed. Emerging drugs like Rilzabrutinib (Sanofi/Principia Biopharma) are in Phase III for ITP treatment.

Velocity Clinical Research appoints Renata Berardocco as Executive Vice President and Managing Director for Latin America, aiming to expand its global network and leverage her experience in multisite networks and patient recruitment.

Top pharmaceutical companies like Pfizer, Roche, Johnson & Johnson, Novartis, Merck, AstraZeneca, Sanofi, GSK, AbbVie, and Bayer lead in innovation, focusing on areas such as mRNA vaccines, cancer treatments, immunology, and gene therapy, shaping the future of healthcare through R&D investments and strategic pivots.

Georg Schett presented data on CD19-directed CAR-T therapies in refractory autoimmune and rheumatic diseases at ACR Convergence 2024, highlighting low relapse rates and faster manufacturing processes.

Global Immuno-Oncology Clinical Trials Market report analyzes current status, future trends, and growth, covering major players like ICON PLC, IQVIA Holdings Inc., Covance, BioNTech, and others. It provides historical, current, and forecast market size, segmentation, and regional analysis. Key factors influencing market dynamics, including drivers, restraints, and projections, are detailed. The report also offers insights into market shares, strategies, and emerging niche segments.